- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1745 |
Product Name |
ADT1745-Human Anti-CD3ExCD20 Bispecific Antibody |
Isotype |
Human IgG1-lambda2_G1-kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3E mAb, Anti-CD3E Monoclonal Antibody, CD3E recombinant antibody, Anti-CD3E Bispecific Antibody, Human Anti-CD20 mAb, CD20 recombinant antibody, Anti-CD20 Monoclonal Antibody, Anti-CD20 Bispecific Antibody |
|
Official Symbol |
CD3ExCD20 |
Target 1 |
CD3E |
Gene ID 1 |
916 |
Target 2 |
CD20 |
Gene ID 2 |
931 |
Species |
Human |
Drug Name |
Epcoritamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2134641-34-0 |
Chemical Formula |
C6471H9999N1735O2007S44 |
Molecular Weight |
149 KDa |
Product Description |
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. |
Mechanism of Action |
Epcoritamab is a humanized bispecific IgG1 antibody that targets CD20 on B-cells and CD3 on T-cells. Unlike other monoclonal antibodies that target a single receptor on the surface of lymphocytes, epcoritamab can recognize and bind two different targets, the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. By targeting both receptors, epcoritamab promotes the release of proinflammatory cytokines and the lysis of CD20+ malignant B-cells through selective T-cell–mediated cytotoxic activity. |
Metabolism |
As a monoclonal antibody, epcoritamab is expected to be metabolized into small peptides by catabolic pathways throughout the body. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ: Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
2. Gonzalez Barca E: Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
|
FAQ
-
+ -
What is CD3E’s role?
CD3E is a T-cell co-receptor. Engaging CD3E recruits T-cells to eliminate CD20-expressing B-cell malignancies.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
Why target CD20?
CD20 is a B-cell surface marker overexpressed in lymphomas and leukemias. -
+ -
What makes the functional pathways of bispecific antibodies flexible?
Bispecific antibodies offer flexibility in their functional pathways as they are able to have two binding sites for different antigens or recognize two different epitopes of an antigen simultaneously.